Andrew Tsai
Stock Analyst at Jefferies
(0.44)
# 3,964
Out of 4,761 analysts
17
Total ratings
26.67%
Success rate
-19.16%
Average return
Main Sectors:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Initiates: Buy | $29 | $10.47 | +176.98% | 1 | Dec 18, 2024 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $165 | $106.28 | +55.25% | 1 | Oct 21, 2024 | |
| RLMD Relmada Therapeutics | Upgrades: Buy | $3.5 → $13 | $0.30 | +4,306.78% | 2 | Sep 17, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $35 | $12.68 | +176.03% | 1 | Jul 2, 2024 | |
| ANRO Alto Neuroscience | Initiates: Buy | $33 | $3.19 | +934.48% | 1 | Feb 27, 2024 | |
| VTGN Vistagen Therapeutics | Upgrades: Buy | $0.2 → $15 | $2.93 | +411.95% | 2 | Dec 7, 2023 | |
| LXRX Lexicon Pharmaceuticals | Initiates: Hold | $3 | $0.71 | +322.54% | 1 | Mar 7, 2023 | |
| ATHA Athira Pharma | Downgrades: Hold | $32 → $3 | $0.43 | +591.09% | 2 | Jun 23, 2022 | |
| BEKE KE Holdings | Upgrades: Overweight | $23 → $16 | $20.90 | -23.44% | 1 | Mar 16, 2022 | |
| VIGL Vigil Neuroscience | Initiates: Buy | $20 | $3.03 | +560.07% | 1 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $70 | $128.60 | -45.57% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.99 | +1,256.78% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $39.73 | -42.11% | 1 | Jun 1, 2020 |
Rocket Pharmaceuticals
Dec 18, 2024
Initiates: Buy
Price Target: $29
Current: $10.47
Upside: +176.98%
Sarepta Therapeutics
Oct 21, 2024
Initiates: Buy
Price Target: $165
Current: $106.28
Upside: +55.25%
Relmada Therapeutics
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $0.30
Upside: +4,306.78%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $12.68
Upside: +176.03%
Alto Neuroscience
Feb 27, 2024
Initiates: Buy
Price Target: $33
Current: $3.19
Upside: +934.48%
Vistagen Therapeutics
Dec 7, 2023
Upgrades: Buy
Price Target: $0.2 → $15
Current: $2.93
Upside: +411.95%
Lexicon Pharmaceuticals
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $0.71
Upside: +322.54%
Athira Pharma
Jun 23, 2022
Downgrades: Hold
Price Target: $32 → $3
Current: $0.43
Upside: +591.09%
KE Holdings
Mar 16, 2022
Upgrades: Overweight
Price Target: $23 → $16
Current: $20.90
Upside: -23.44%
Vigil Neuroscience
Feb 1, 2022
Initiates: Buy
Price Target: $20
Current: $3.03
Upside: +560.07%
Sep 20, 2021
Maintains: Buy
Price Target: $55 → $70
Current: $128.60
Upside: -45.57%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $1.99
Upside: +1,256.78%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $39.73
Upside: -42.11%